Nonablative fractional laser treatment helps prevent nonmelanoma skin cancer: Study

Written By :  Dr. Kamal Kant Kohli
Published On 2023-02-25 04:15 GMT   |   Update On 2023-02-25 10:51 GMT

USA: Nonablative fractional lasers (NAFL) treatment is linked with a decreased risk of subsequent development of facial keratinocyte carcinoma (KC), a recent study published in Dermatologic Surgery has shown. Squamous cell carcinoma and basal cell carcinoma are collectively known as keratinocyte carcinoma. The study, conducted by a team of researchers from Massachusetts General Hospital,...

Login or Register to read the full article

USA: Nonablative fractional lasers (NAFL) treatment is linked with a decreased risk of subsequent development of facial keratinocyte carcinoma (KC), a recent study published in Dermatologic Surgery has shown. Squamous cell carcinoma and basal cell carcinoma are collectively known as keratinocyte carcinoma. 

The study, conducted by a team of researchers from Massachusetts General Hospital, reveals an easy-to-implement strategy to protect individuals’ skin health.

Nonablative fractional lasers deliver heat in a fractional manner that leaves it fully intact after treatment (unlike ablative fractional lasers that remove the top layer of skin), and they’re currently used to treat scars, sun-damaged skin, age spots, and more; however, their effectiveness for preventing skin damage is unknown.

To investigate, Mathew Avram, MD, JD, director of the Mass General Dermatology Laser & Cosmetic Center, and his colleagues studied patients who had been successfully treated for facial keratinocyte carcinoma in the past. Such patients have a 35% risk of experiencing a subsequent keratinocyte carcinoma within 3 years and a 50% risk within 5 years.

In the study, 43 patients received NAFL therapy and 52 served as controls and did not receive NAFL therapy.

The rate of subsequent facial keratinocyte carcinoma development over an average follow-up of more than 6 years was 20.9% in NAFL-treated patients and 40.4% in controls, indicating that patients treated with NAFL had about half the risk.

When controlling for age, gender, and skin type, control patients were 2.65-times more likely to develop a new facial keratinocyte carcinoma than NAFL-treated patients.

Also, among patients who developed a facial keratinocyte carcinoma, the time to development was significantly longer in patients treated with NAFL than untreated patients.

“These findings suggest that NAFL treatment may have an important role in protecting against subsequent keratinocyte carcinomas,” says Avram.

“While the mechanism of NAFL’s protective effect is not completely understood, it is suspected that NAFL treatment reduces the overall burden of photodamaged keratinocytes and may promote a wound healing response, which gives healthy skin cells a selective advantage.”

Avram noted that additional studies are warranted to more critically assess the role of NAFL in skin cancer prevention, to reveal the duration of its protective effects, and to determine optimal treatment parameters.

“Based on this research, it’s encouraged for patients to have nonablative laser treatments to help prevent skin cancer if they are at risk or notice abnormalities,” says Avram.

Additionally, it’s important to take proper precautions to reduce the risk of skin cancer, including:

• Wearing sunscreen daily

• Wearing hats and protective clothing in the sun

• Performing self-skin examinations

Reference:

Benson, Travis A. Hibler, Brian P.  Kotliar, Dylan , Avram, Mathew  Nonablative Fractional Laser Treatment Is Associated With a Decreased Risk of Subsequent Facial Keratinocyte Carcinoma Development. Dermatologic Surgery 49(2):p 149-154, February 2023. | DOI: 10.1097/DSS.0000000000003672

Tags:    
Article Source : Dermatologic Surgery

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News